Literature DB >> 22942823

Treating Anaplastic Lymphoma Kinase-Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of Crizotinib.

Nathan A Pennell.   

Abstract

Entities:  

Year:  2012        PMID： 22942823      PMCID： PMC3348597          DOI： 10.1200/JOP.2012.000551

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  5 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.

Authors:  Jin Ho Paik; Chang-Min Choi; Hyojin Kim; Se Jin Jang; Gheeyoung Choe; Dong Kwan Kim; Hwa Jung Kim; Hoil Yoon; Choon-Taek Lee; Sanghoon Jheon; Ji-Young Choe; Jin-Haeng Chung
Journal:  Lung Cancer       Date:  2011-11-30       Impact factor: 5.705

3.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

4.  ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

Authors:  Sanjay Popat; David Gonzalez; Toon Min; John Swansbury; Melissa Dainton; James G Croud; Alexandra J Rice; Andrew G Nicholson
Journal:  Lung Cancer       Date:  2011-08-19       Impact factor: 5.705

Review 5.  Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.

Authors:  C Gridelli; F De Marinis; M Di Maio; D Cortinovis; F Cappuzzo; T Mok
Journal:  Lung Cancer       Date:  2011-01-08       Impact factor: 5.705
  5 in total
  1 in total

1.  Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma.

Authors:  Arabinda Das; Ron Ron Cheng; Megan L T Hilbert; Yaenette N Dixon-Moh; Michele Decandio; William Alex Vandergrift; Naren L Banik; Scott M Lindhorst; David Cachia; Abhay K Varma; Sunil J Patel; Pierre Giglio
Journal:  Cancer Growth Metastasis       Date:  2015-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.